Remove Clinical Trials Remove Therapy Remove Treatment
article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. ABOUT SANTÉ CANNABIS.

article thumbnail

FDA Approves Ketamine Nasal Spray as First and Only Standalone Therapy for Treatment-Resistant Depression

Veriheal

In January, the US Food and Drug Administration (FDA) approved the Johnson & Johnson brand nasal spray, Spravato®, as the world’s first and only monotherapy for addressing treatment-resistant cases of major depressive disorder (MDD). However, doctors do not consider esketamine a first-line treatment for depression.

Therapy 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medical Marijuana Offers Hope for Treatment of PTSD

FloridaMarijuana.net

Treatment usually aims at reducing reactions and to diminishing the acuity of the reactions. Treatments also seek to increase the subject’s ability to manage trauma-related emotions and to greater confidence in coping abilities. The post Medical Marijuana Offers Hope for Treatment of PTSD appeared first on.

Treatment 182
article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

article thumbnail

Clinical Trial: Transdermal Application of CBD Effective in Patients with Myofascial Pain

NORML

Polish investigators conducted a randomized, double-blind placebo-controlled trial assessing the efficacy of twice-daily transdermal CBD administration on 60 patients with TMD over a period of 14 days. Subjects receiving treatment reported no adverse effects.

article thumbnail

A Bipartisan Bill Is Pledging $75 Million for Psychedelic Research in Military PTSD Treatment

Veriheal

Recognizing that the efficacy of treatment relies not only on the therapeutic substances themselves but also on the skill and knowledge of the individuals administering them, this bill explicitly supports the training of practitioners. This could foster a pool of experts well-versed in applying psychedelic-assisted therapy.

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. With enrollment completed, treatment is expected to conclude towards the end of March and results are anticipated to be announced in the second half of calendar 2020.